NO964516L - Anvendelse av et salt for fremstilling av et farmasöytisk preparat - Google Patents

Anvendelse av et salt for fremstilling av et farmasöytisk preparat

Info

Publication number: NO964516L
Authority: NO; Norway
Prior art keywords: disease; salt; preparation; pharmaceutical composition; prepn
Prior art date: 1995-10-26

Application number

NO964516A

Other languages

English (en)

Norwegian (no)

Other versions

NO964516D0 (no

Inventor

Olivier De Lacharriere

Lionel Breton

Original Assignee

Oreal

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1995-10-26

Filing date

1996-10-24

Publication date

1997-04-28

1996-10-24 Application filed by Oreal filed Critical Oreal

1996-10-24 Publication of NO964516D0 publication Critical patent/NO964516D0/no

1997-04-28 Publication of NO964516L publication Critical patent/NO964516L/no

Links

150000003839 salts Chemical class 0.000 title abstract 2
239000008194 pharmaceutical composition Substances 0.000 title 1
208000024827 Alzheimer disease Diseases 0.000 abstract 1
229910052684 Cerium Inorganic materials 0.000 abstract 1
206010011224 Cough Diseases 0.000 abstract 1
229910052692 Dysprosium Inorganic materials 0.000 abstract 1
206010014561 Emphysema Diseases 0.000 abstract 1
229910052691 Erbium Inorganic materials 0.000 abstract 1
229910052693 Europium Inorganic materials 0.000 abstract 1
229910052688 Gadolinium Inorganic materials 0.000 abstract 1
208000007882 Gastritis Diseases 0.000 abstract 1
208000005577 Gastroenteritis Diseases 0.000 abstract 1
229910052689 Holmium Inorganic materials 0.000 abstract 1
208000006264 Korsakoff syndrome Diseases 0.000 abstract 1
229910052765 Lutetium Inorganic materials 0.000 abstract 1
208000008238 Muscle Spasticity Diseases 0.000 abstract 1
229910052779 Neodymium Inorganic materials 0.000 abstract 1
208000018737 Parkinson disease Diseases 0.000 abstract 1
229910052777 Praseodymium Inorganic materials 0.000 abstract 1
229910052773 Promethium Inorganic materials 0.000 abstract 1
208000003782 Raynaud disease Diseases 0.000 abstract 1
208000012322 Raynaud phenomenon Diseases 0.000 abstract 1
229910052772 Samarium Inorganic materials 0.000 abstract 1
208000007107 Stomach Ulcer Diseases 0.000 abstract 1
229910052771 Terbium Inorganic materials 0.000 abstract 1
229910052775 Thulium Inorganic materials 0.000 abstract 1
ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 abstract 1
206010046543 Urinary incontinence Diseases 0.000 abstract 1
201000008485 Wernicke-Korsakoff syndrome Diseases 0.000 abstract 1
229910052769 Ytterbium Inorganic materials 0.000 abstract 1
HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 abstract 1
229910052788 barium Inorganic materials 0.000 abstract 1
DSAJWYNOEDNPEQ-UHFFFAOYSA-N barium atom Chemical compound [Ba] DSAJWYNOEDNPEQ-UHFFFAOYSA-N 0.000 abstract 1
GWXLDORMOJMVQZ-UHFFFAOYSA-N cerium Chemical compound [Ce] GWXLDORMOJMVQZ-UHFFFAOYSA-N 0.000 abstract 1
229910017052 cobalt Inorganic materials 0.000 abstract 1
239000010941 cobalt Substances 0.000 abstract 1
GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical compound [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 abstract 1
201000003146 cystitis Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
KBQHZAAAGSGFKK-UHFFFAOYSA-N dysprosium atom Chemical compound [Dy] KBQHZAAAGSGFKK-UHFFFAOYSA-N 0.000 abstract 1
UYAHIZSMUZPPFV-UHFFFAOYSA-N erbium Chemical compound [Er] UYAHIZSMUZPPFV-UHFFFAOYSA-N 0.000 abstract 1
OGPBJKLSAFTDLK-UHFFFAOYSA-N europium atom Chemical compound [Eu] OGPBJKLSAFTDLK-UHFFFAOYSA-N 0.000 abstract 1
UIWYJDYFSGRHKR-UHFFFAOYSA-N gadolinium atom Chemical compound [Gd] UIWYJDYFSGRHKR-UHFFFAOYSA-N 0.000 abstract 1
201000005917 gastric ulcer Diseases 0.000 abstract 1
KJZYNXUDTRRSPN-UHFFFAOYSA-N holmium atom Chemical compound [Ho] KJZYNXUDTRRSPN-UHFFFAOYSA-N 0.000 abstract 1
230000000968 intestinal effect Effects 0.000 abstract 1
229910052746 lanthanum Inorganic materials 0.000 abstract 1
FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 abstract 1
OHSVLFRHMCKCQY-UHFFFAOYSA-N lutetium atom Chemical compound [Lu] OHSVLFRHMCKCQY-UHFFFAOYSA-N 0.000 abstract 1
WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical compound [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 abstract 1
201000006417 multiple sclerosis Diseases 0.000 abstract 1
QEFYFXOXNSNQGX-UHFFFAOYSA-N neodymium atom Chemical compound [Nd] QEFYFXOXNSNQGX-UHFFFAOYSA-N 0.000 abstract 1
PUDIUYLPXJFUGB-UHFFFAOYSA-N praseodymium atom Chemical compound [Pr] PUDIUYLPXJFUGB-UHFFFAOYSA-N 0.000 abstract 1
VQMWBBYLQSCNPO-UHFFFAOYSA-N promethium atom Chemical compound [Pm] VQMWBBYLQSCNPO-UHFFFAOYSA-N 0.000 abstract 1
KZUNJOHGWZRPMI-UHFFFAOYSA-N samarium atom Chemical compound [Sm] KZUNJOHGWZRPMI-UHFFFAOYSA-N 0.000 abstract 1
208000018198 spasticity Diseases 0.000 abstract 1
229910052712 strontium Inorganic materials 0.000 abstract 1
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
GZCRRIHWUXGPOV-UHFFFAOYSA-N terbium atom Chemical compound [Tb] GZCRRIHWUXGPOV-UHFFFAOYSA-N 0.000 abstract 1
229910052718 tin Inorganic materials 0.000 abstract 1
239000011135 tin Substances 0.000 abstract 1
NAWDYIZEMPQZHO-UHFFFAOYSA-N ytterbium Chemical compound [Yb] NAWDYIZEMPQZHO-UHFFFAOYSA-N 0.000 abstract 1
229910052727 yttrium Inorganic materials 0.000 abstract 1
VWQVUPCCIRVNHF-UHFFFAOYSA-N yttrium atom Chemical compound [Y] VWQVUPCCIRVNHF-UHFFFAOYSA-N 0.000 abstract 1
229910052725 zinc Inorganic materials 0.000 abstract 1
239000011701 zinc Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/32—Manganese; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Inorganic Chemistry (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Pulmonology (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

NO964516A 1995-10-26 1996-10-24 Anvendelse av et salt for fremstilling av et farmasöytisk preparat NO964516L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
FR9512657A FR2740342B1 (fr)	1995-10-26	1995-10-26	Utilisation de sel de lanthanide, de manganese, de lithium, d'etain, de zinc ou d'yttrium, de cobalt, de baryum, de strontium dans des compositions pharmaceutiques

Publications (2)

Publication Number	Publication Date
NO964516D0 NO964516D0 (no)	1996-10-24
NO964516L true NO964516L (no)	1997-04-28

Family

ID=9483958

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO964516A NO964516L (no)	1995-10-26	1996-10-24	Anvendelse av et salt for fremstilling av et farmasöytisk preparat

Country Status (8)

Country	Link
EP (1)	EP0770391B1 (de)
JP (1)	JPH09169656A (de)
AT (1)	ATE173933T1 (de)
CA (1)	CA2188891A1 (de)
DE (1)	DE69601061T2 (de)
ES (1)	ES2127612T3 (de)
FR (1)	FR2740342B1 (de)
NO (1)	NO964516L (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9621273D0 (en)	1996-10-11	1996-11-27	Cortecs Ltd	Therapeutic method
AT405017B (de) *	1997-10-06	1999-04-26	Jakoby Marie Luise	Mittel zur stimulation der körpereigenen abwehr
GB0012487D0 (en) *	2000-05-24	2000-07-12	Pfylori Limited	Use of metal compounds to treat gastrointestinal infections
DE10253634A1 (de) *	2002-11-13	2004-05-27	Biotronik Meß- und Therapiegeräte GmbH & Co. Ingenieurbüro Berlin	Endoprothese
JP2007023010A (ja) *	2005-07-19	2007-02-01	Toshiro Azegami	閉経後のホルモンバランス調整及びパーキンソン症の予防改善目的の経口組成物
EP1972342A4 (de) *	2005-07-29	2011-01-12	Univ Barcelona	Pharmazeutische zusammensetzungen aus einem wolframsalz (vi) zur behandlung von neurodegenerativen störungen, insbesondere alzheimer-krankheit und schizophrenie

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB997975A (en) *	1964-01-31	1965-07-14	Aristotelis Papageorgiou Lambo	Pharmaceutical compositions containing a cresol or a mixture of cresols
GB1209093A (en) *	1968-07-16	1970-10-14	Delandale Lab Ltd	Pharmaceutical preparation
US4386072A (en) *	1981-06-26	1983-05-31	Horrobin David F	Treatment of disorders of inflammation and immunity and disorders associated with smooth muscle spasm and compositions therefor
AU556817B2 (en) *	1982-02-03	1986-11-20	Efamol Limited	Topical application of a lithium salt and dihomo-alpha- linolenic acid
MTP930B (en) *	1982-04-30	1984-04-10	Delandale Labs Ltd	Substained release lithium-containing tablets and method for their manufacture
GB2133285A (en) *	1983-01-12	1984-07-25	Alec James Coppen	Pharmaceutical compositions
GB8320203D0 (en) *	1983-07-27	1983-09-01	Horrobin D F	Anti-viral compositions
AU599567B2 (en) *	1984-03-01	1990-07-26	Vernon Erk	Method of treating memory disorders of the elderly
GB8601915D0 (en) *	1986-01-27	1986-03-05	Efamol Ltd	Pharmaceutical compositions
ATE129254T1 (de) *	1987-03-19	1995-11-15	Arthropharm Pty Ltd	Antientzündungsmittel und zusammensetzungen.
JPH01172325A (ja) *	1987-12-28	1989-07-07	Terumo Corp	抗リウマチ剤
JPH01287033A (ja) *	1988-05-13	1989-11-17	Terumo Corp	抗リウマチ剤
JPH03120220A (ja) *	1989-10-04	1991-05-22	Natterer Siegfried	調製薬剤およびその製造方法
JP3121859B2 (ja) *	1991-05-31	2001-01-09	利博山瀬	抗ウイルス剤
HU207799B (en) *	1991-07-24	1993-06-28	Beres Export Import Rt	Process for producing pharmaceutical composition for influencing the reticuloendothelial system, for treating chronic pain symptomes of degenerative locomotor disorders or tumors, and for treating mucoviscidosis
JPH05117157A (ja) *	1991-09-04	1993-05-14	Kao Corp	象牙質知覚過敏予防・治療剤及びこれを含有する口腔用組成物
US6455076B1 (en) *	1994-12-21	2002-09-24	Gary S. Hahn	Formulations and methods for reducing skin irritation
US5716625A (en) *	1994-12-21	1998-02-10	Cosmederm Technologies	Formulations and methods for reducing skin irritation

1995
- 1995-10-26 FR FR9512657A patent/FR2740342B1/fr not_active Expired - Fee Related
1996
- 1996-10-14 EP EP96402181A patent/EP0770391B1/de not_active Expired - Lifetime
- 1996-10-14 DE DE69601061T patent/DE69601061T2/de not_active Expired - Fee Related
- 1996-10-14 AT AT96402181T patent/ATE173933T1/de not_active IP Right Cessation
- 1996-10-14 ES ES96402181T patent/ES2127612T3/es not_active Expired - Lifetime
- 1996-10-24 NO NO964516A patent/NO964516L/no not_active Application Discontinuation
- 1996-10-25 CA CA002188891A patent/CA2188891A1/fr not_active Abandoned
- 1996-10-25 JP JP8284317A patent/JPH09169656A/ja active Pending

Also Published As

Publication number	Publication date
FR2740342A1 (fr)	1997-04-30
EP0770391B1 (de)	1998-12-02
NO964516D0 (no)	1996-10-24
ATE173933T1 (de)	1998-12-15
ES2127612T3 (es)	1999-04-16
CA2188891A1 (fr)	1997-04-27
JPH09169656A (ja)	1997-06-30
FR2740342B1 (fr)	1997-12-19
EP0770391A3 (de)	1997-05-07
EP0770391A2 (de)	1997-05-02
DE69601061T2 (de)	1999-04-22
DE69601061D1 (de)	1999-01-14

Legal Events

Date	Code	Title	Description
2002-06-24	FC2A	Withdrawal, rejection or dismissal of laid open patent application

Publication	Publication Date	Title
NO964515L (no)	1997-04-28	Anvendelse av et salt for fremstilling av et farmasöytisk eller dermatologisk preparat
IL109684A0 (en)	1994-12-29	PHARMACEUTICAL COMPOUNDS FOR INHIBITING GASTRIC ACPharmaceutical compounds for inhibiting gastric acID SECRETION id secretion
SI0654264T1 (en)	2001-10-31	Use of venlafaxine or of an aryloxy propanamine compound for the manufacture of a medicament for the treatment of urinary incontinence
GR3019345T3 (en)	1996-06-30	A tramadol N-oxide material, enantiomers and compositions thereof, and their use
GR3035913T3 (en)	2001-08-31	Polyaminated ligands, metal complexes, process for their preparation and diagnostic and therapeutic applications.
TW267175B (de)	1996-01-01
ES2130481T3 (es)	1999-07-01	Prepolimeros de isocianato, procedimiento para su preparacion y su uso.
AU4015693A (en)	1994-01-13	Polysuccinimide polymers and process for preparing polysuccinimide polymers
NO964516D0 (no)	1996-10-24	Anvendelse av et salt for fremstilling av et farmasöytisk preparat
CA2060208A1 (en)	1991-10-11	Wound healing
CA2246584A1 (en)	1999-03-05	Method of treating tourette's syndrome
EP0264948A3 (en)	1989-06-14	Aromatic dicarboxylic acid diallyl ester derivative, prepolymer derived from the derivative and curable resin composition containing the derivative
DE3570639D1 (en)	1989-07-06	Method for the preparation of fine hexagonal ferrite powders, in particular, for magnetic recording
ATE261986T1 (de)	2004-04-15	Polyol-aminosäureverbindungen mit aktivität gegen helicobacter pylori
DE69525439D1 (de)	2002-03-21	Antibiotikum und verfahren zu dessen herstellung
EP0461948A3 (en)	1992-06-03	Process for the removal of n vinylcarbazole from poly (n vinylcarbazole)
Higuchi et al.	1988	The Oxidation of Fe (II) in Weakly Acidic Solution Containing Cu (II)
Kalenda	1993	ANTICORROSIVE SEALANT DISPERSIONS
JPS5269949A (en)	1977-06-10	Polyolefin resin composition
JPS52131535A (en)	1977-11-04	Novel aromatic diamine compound and fire-retarding polyamide resinous composition containing same